Michael Birrer Institution-verified

Sourced from institutional research profiles (UAMS TRI or ARA).

High Impact

Director

UAMS

Last publication 2026 Last refreshed 2026-05-16

faculty

mjbirrer@uams.edu

126 h-index 1080 pubs 103,407 cited

Research Areas

Links

ORCID Lab Website Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Michael Birrer's research primarily investigates ovarian cancer, with a focus on identifying potential therapeutic targets and understanding factors that influence treatment response and recurrence. He has explored multiomic analyses to identify genes like CPT1A as targets in platinum-refractory high-grade serous ovarian cancer. His work also examines the impact of mechanical forces on ovarian cancer progression and genetic variants affecting PARP inhibitor sensitivity in advanced ovarian cancer.

Birrer has also been involved in evaluating the safety and tolerability of novel therapeutic agents, such as mirvetuximab soravtansine for folate receptor alpha–expressing recurrent ovarian cancer and a gorilla adenovirus-based immunotherapy in combination with pembrolizumab for recurrent or metastatic cervical cancer. His scholarship metrics include an h-index of 126, over 1080 publications, and more than 103,000 citations, designating him as a highly cited researcher.

Metrics

h-index: 126
Publications: 1080
Citations: 103,407

Selected Publications

Abstract 3970: Genome wide testing of archived ovarian and uterine carcinosarcoma FFPE tissue using FusionPlus Hi-C to determine HRD status (2026)

DOI OpenAlex
Quality-of-life outcomes in newly diagnosed advanced cancer: subgroup analysis – a case for individual differences (2026)

DOI OpenAlex
Abstract A044: Application of HRDefine: a biomarker for identifying root causes of homologous recombination deficiency to a phase 3, randomized, placebo-controlled trial of veliparib in front-line treatment of advanced ovarian cancer (VELIA/GOG-3005) (2025)

DOI OpenAlex
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer (2025)

7 citations DOI OpenAlex
Single-cell analysis of ovarian myeloid cells identifies age-associated changes in macrophages and signaling dynamics (2025)

6 citations DOI OpenAlex
miRNA(s) expression as predictive biomarkers in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 NIH Cancer Moonshot. (2025)

DOI OpenAlex
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary (2024)

19 citations DOI OpenAlex
A spatial proteomic study of platinum-refractory, high-grade serous ovarian cancer implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment (2024)

DOI OpenAlex
Treatment monitoring utilizing ctDNA-based molecular residual disease detection in early-stage endometrial cancer (2024)

DOI OpenAlex
A phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer. (2024)

1 citation DOI OpenAlex
Single-cell analysis of ovarian myeloid cells identifies aging associated changes in macrophages and signaling dynamics (2024)

4 citations DOI OpenAlex
A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies. (2024)

3 citations DOI OpenAlex
Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas. (2024)

23 citations DOI OpenAlex
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC). (2024)

16 citations DOI OpenAlex
A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment (2024)

3 citations DOI OpenAlex